02.25.25 -- FDA Issues Draft Guidance On The Use Of AI To Support Regulatory Decision-Making For Drug And Biological Products

Devoting early-phase resources for solid form understanding and screening during a drug’s development lifecycle is critical, as doing so can help save time and resources on the path to market.

Explore four essential questions to ask yourself when developing a PROTAC molecule to ensure you’re on the right track to protein degradation success.

Discover a system that automates mAb purification, reducing time and costs in cell line development while improving reproducibility, with faster processing than traditional methods.

Many small and/or early-stage companies are not aware of the need, or the possibility, of finding a CDMO that specializes in meeting their specific requirements.

To meet ambitious orphan drug development timelines, CDMOs must be able to scale quickly to progress from early clinical development to validation and commercial launch.

When it comes to process development, timing, technology, and partners all merit careful consideration. Explore expert insights into these three crucial factors.

In this presentation, we introduce the human Airway Lung-Chip, which can model influenza virus infection and evolution in vitro and evaluate therapeutics for both influenza and SARS-CoV-2.

Explore two case studies where lung cancer therapies were delivered to the lung by dry powder inhaler, confirming local delivery is a promising route to treat lung cancer.